Therapy for neuromuscular disorders

Current Opinion in Genetics and Development

Volumn 19, Issue 3, 2009, Pages 290-297

  Arnett, Andrea LH ^a   Chamberlain, Joel R ^a   Chamberlain, Jeffrey S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SARCOGLYCAN; ANTISENSE OLIGONUCLEOTIDE; CALPAIN 3; CHLORIDE CHANNEL; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; DYSTROPHIN; HORMONE RECEPTOR AFFECTING AGENT; LENTIVIRUS VECTOR; LOSARTAN; MYOTONIC DYSTROPHY PROTEIN KINASE; PARVOVIRUS VECTOR; PTC 124; SMALL INTERFERING RNA; SMALL NUCLEAR RNA; SMT 1100; SOMATOMEDIN C; STEROID; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; BECKER MUSCULAR DYSTROPHY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; EXON; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE EXPRESSION; GENE MUTATION; GENE REPLACEMENT THERAPY; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MOTOR NEURON DISEASE; MUSCULAR DYSTROPHY; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SPINAL MUSCULAR ATROPHY; STEM CELL TRANSPLANTATION; THERAPY EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; BIOMEDICAL RESEARCH; DYSTROPHIN; GENE THERAPY; HUMANS; MULTIPOTENT STEM CELLS; MUTATION; NEUROMUSCULAR DISEASES; RNA INTERFERENCE; STEM CELL TRANSPLANTATION;

ANIMALIA;

EID: 68649123826     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2009.03.005     Document Type: Review

References (80)

1. Wilton S.D., and Fletcher S. Exon skipping and Duchenne muscular dystrophy: hope, hype and how feasible?. Neurol India 56 (2008) 254-262
2. Dominski Z., and Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci U S A 90 (1993) 8673-8677
3. Aartsma-Rus A., and van Ommen G.J. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13 (2007) 1609-1624
4. Takeshima Y., Nishio H., Sakamoto H., Nakamura H., and Matsuo M. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J Clin Invest 95 (1995) 515-520
5. Wilton S.D., Fall A.M., Harding P.L., McClorey G., Coleman C., and Fletcher S. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 15 (2007) 1288-1296
6. Wu B., Moulton H.M., Iversen P.L., Jiang J., Li J., Spurney C.F., Sali A., Guerron A.D., Nagaraju K., Doran T., et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A 105 (2008) 14814-14819. The authors demonstrate restoration of dystrophin expression in the mdx mouse using antisense oligonucleotides conjugated to an arginine-rich cell-penetrating peptide. This is the first paper to achieve successful cardiac dystrophin expression following systemic injection of morpholino antisense oligonucleotides. Questions remain about how well the added peptide will be tolerated by the host immune system.
7. Mitrpant C., Fletcher S., Iversen P.L., and Wilton S.D. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping. J Gene Med 11 (2009) 46-56
8. van Vliet L., de Winter C.L., van Deutekom J.C., van Ommen G.J., and Aartsma-Rus A. Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med Genet 9 (2008) 105
9. McClorey G., Moulton H.M., Iversen P.L., Fletcher S., and Wilton S.D. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13 (2006) 1373-1381
10. Lu Q.L., Mann C.J., Lou F., Bou-Gharios G., Morris G.E., Xue S.A., Fletcher S., Partridge T.A., and Wilton S.D. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9 (2003) 1009-1014
11. Fletcher S., Honeyman K., Fall A.M., Harding P.L., Johnsen R.D., and Wilton S.D. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8 (2006) 207-216
12. McClorey G., Fletcher S., and Wilton S. Splicing intervention for Duchenne muscular dystrophy. Curr Opin Pharmacol 5 (2005) 529-534
13. Yin H., Lu Q., and Wood M. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 16 (2008) 38-45
14. Fletcher S., Honeyman K., Fall A.M., Harding P.L., Johnsen R.D., Steinhaus J.P., Moulton H.M., Iversen P.L., and Wilton S.D. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 15 (2007) 1587-1592
15. Townsend D., Yasuda S., Li S., Chamberlain J.S., and Metzger J.M. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 16 (2008) 832-835. Here it is shown that, in comparison to fully dystrophin-deficient animals, mdx mice treated such that they express dystrophin only in skeletal muscle develop a worse cardiomyopathy. These studies emphasize the consequences of neglecting to treat cardiac muscle in DMD patients.
16. Jearawiriyapaisarn N., Moulton H.M., Buckley B., Roberts J., Sazani P., Fucharoen S., Iversen P.L., and Kole R. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16 (2008) 1624-1629
17. Yin H., Moulton H.M., Seow Y., Boyd C., Boutilier J., Iverson P., and Wood M.J. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17 (2008) 3909-3918
18. Abes R., Arzumanov A., Moulton H., Abes S., Ivanova G., Gait M.J., Iversen P., and Lebleu B. Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J Pept Sci 14 (2008) 455-460
19. Doran T.J., Lu P.J., Vanier G.S., Collins M.J., Wu B., and Lu Q.L. Microwave irradiation enhances gene and oligonucleotide delivery and induces effective exon skipping in myoblasts. Gene Ther 16 (2009) 119-126
20. Wheeler T.M., Lueck J.D., Swanson M.S., Dirksen R.T., and Thornton C.A. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 117 (2007) 3952-3957. Morpholino antisense oligonucleotides targeted to the 3′ splice site of ClC-1 exon 7a restored normal ClC-1 splicing in a mouse model of myotonic dystrophy and eliminated myotonic discharges, indicating that targeting the ClC-1 splicing defect may be an effective treatment strategy.
21. Cho D.H., and Tapscott S.J. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta 1772 (2007) 195-204
22. Charlet B.N., Savkur R.S., Singh G., Philips A.V., Grice E.A., and Cooper T.A. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 10 (2002) 45-53
23. Davidson B. RNAi therapeutics. Special Issue. Introduction. Gene Ther 13 (2006) 463
24. Tawil R., and Van Der Maarel S.M. Facioscapulohumeral muscular dystrophy. Muscle Nerve 34 (2006) 1-15
25. Bosnakovski D., Lamb S., Simsek T., Xu Z., Belayew A., Perlingeiro R., and Kyba M. DUX4c, an FSHD candidate gene, interferes with myogenic regulators and abolishes myoblast differentiation. Exp Neurol 214 (2008) 87-96
26. Dixit M., Ansseau E., Tassin A., Winokur S., Shi R., Qian H., Sauvage S., Matteotti C., van Acker A.M., Leo O., et al. DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci U S A 104 (2007) 18157-18162
27. Gabellini D., D'Antona G., Moggio M., Prelle A., Zecca C., Adami R., Angeletti B., Ciscato P., Pellegrino M.A., Bottinelli R., et al. Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature 439 (2006) 973-977
28. Denti M.A., Incitti T., Sthandier O., Nicoletti C., De Angelis F.G., Rizzuto E., Auricchio A., Musaro A., and Bozzoni I. Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum Gene Ther 19 (2008) 601-608
29. Benchaouir R., Meregalli M., Farini A., D'Antona G., Belicchi M., Goyenvalle A., Battistelli M., Bresolin N., Bottinelli R., Garcia L., et al. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 1 (2007) 646-657
30. Abmayr S, Chamberlain JS: The structure and function of dystrophin. In The Molecular Mechanisms of Muscular Dystrophy. Edited by Winder S. Landes Bioscience; 2006.
31. Foster K., Foster H., and Dickson J.G. Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 13 (2006) 1677-1685
32. Harper S.Q., Hauser M.A., DelloRusso C., Duan D., Crawford R.W., Phelps S.F., Harper H.A., Robinson A.S., Engelhardt J.F., Brooks S.V., et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8 (2002) 253-261
33. Gregorevic P., Blankinship M.J., Allen J.M., Crawford R.W., Meuse L., Miller D.G., Russell D.W., and Chamberlain J.S. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10 (2004) 828-834
34. Gregorevic P., Blankinship M.J., Allen J.M., and Chamberlain J.S. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther 16 (2008) 657-664. The authors show that old dystrophic mdx mice remain amenable to treatment via systemic administration of AAV vectors encoding microdystrophin. These results suggest that current gene therapy strategies may be applicable to both young patients and those with advanced dystrophic pathology.
35. Gregorevic P., Allen J.M., Minami E., Blankinship M.J., Haraguchi M., Meuse L., Finn E., Adams M.E., Froehner S.C., Murry C.E., et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12 (2006) 787-789
36. Rodino-Klapac L.R., Janssen P.M., Montgomery C.L., Coley B.D., Chicoine L.G., Clark K.R., and Mendell J.R. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J Transl Med 5 (2007) 45
37. Yue Y., Ghosh A., Long C., Bostick B., Smith B.F., Kornegay J.N., and Duan D. A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 16 (2008) 1944-1952. Systemic injection of neonatal dogs generated robust, whole body gene expression. Significantly, expression was maintained for over six months without the need for pharmacological intervention or immune suppression.
38. Wang Z., Allen J.M., Riddell S.R., Gregorevic P., Storb R., Tapscott S.J., Chamberlain J.S., and Kuhr C.S. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 18 (2007) 18-26
39. Yuasa K., Yoshimura M., Urasawa N., Ohshima S., Howell J.M., Nakamura A., Hijikata T., Miyagoe-Suzuki Y., and Takeda S. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 14 (2007) 1249-1260
40. Ohshima S., Shin J.H., Yuasa K., Nishiyama A., Kira J., Okada T., and Takeda S. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 17 (2009) 73-80
41. Wang Z., Kuhr C.S., Allen J.M., Blankinship M., Gregorevic P., Chamberlain J.S., Tapscott S.J., and Storb R. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15 (2007) 1160-1166. Sustained expression of microdystrophin was achieved following intramuscular injection of rAAV6 encoding a canine microdystrophin. Maintenance of expression was attained using a transient immunosuppressive regimen. These data suggest that, while an immune response to AAV capsid is likely to occur in dystrophic individuals, it can likely be prevented using transient immunosuppression.
42. Odom G.L., Gregorevic P., Allen J.M., Finn E., and Chamberlain J.S. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther 16 (2008) 1539-1545. The authors demonstrate the functionality of a microutrophin construct. This approach may be an important and viable alternative if dystrophin-based constructs elicit a cellular immune response in DMD patients, which seems likely. The endogenous, ubiquitous expression of utrophin increases the likelihood that a patient may develop immune tolerance of a utrophin-based transgene.
43. Mattei E., Corbi N., Di Certo M.G., Strimpakos G., Severini C., Onori A., Desantis A., Libri V., Buontempo S., Floridi A., et al. Utrophin up-regulation by an artificial transcription factor in transgenic mice. PLoS ONE 2 (2007) e774
44. Goyenvalle A., Vulin A., Fougerousse F., Leturcq F., Kaplan J.C., Garcia L., and Danos O. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306 (2004) 1796-1799
45. Kanadia R.N., Shin J., Yuan Y., Beattie S.G., Wheeler T.M., Thornton C.A., and Swanson M.S. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A 103 (2006) 11748-11753
46. Daniele N., Richard I., and Bartoli M. Ins and outs of therapy in limb girdle muscular dystrophies. Int J Biochem Cell Biol 39 (2007) 1608-1624
47. Muller O.J., and Lochmuller H. Sarcoglycans take center stage in gene transfer therapy. Neurology 71 (2008) 234-235
48. Rodino-Klapac L.R., Lee J.S., Mulligan R.C., Clark K.R., and Mendell J.R. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology 71 (2008) 240-247
49. Pacak C.A., Walter G.A., Gaidosh G., Bryant N., Lewis M.A., Germain S., Mah C.S., Campbell K.P., and Byrne B.J. Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther 15 (2007) 1775-1781
50. Nishiyama A., Ampong B.N., Ohshima S., Shin J.H., Nakai H., Imamura M., Miyagoe-Suzuki Y., Okada T., and Takeda S. Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice. Hum Gene Ther 19 (2008) 719-730
51. Bartoli M., Roudaut C., Martin S., Fougerousse F., Suel L., Poupiot J., Gicquel E., Noulet F., Danos O., and Richard I. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol Ther 13 (2006) 250-259
52. Qiao C., Li J., Jiang J., Zhu X., Wang B., Li J., and Xiao X. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 19 (2008) 241-254
53. Qiao C., Li J., Zheng H., Bogan J., Li J., Yuan Z., Zhang C., Bogan D., Kornegay J., and Xiao X. Hydrodynamic limb vein injection of AAV8 canine myostatin propeptide gene in normal dogs enhances muscle growth. Hum Gene Ther 20 (2008) 1-10
54. Bartoli M., Poupiot J., Vulin A., Fougerousse F., Arandel L., Daniele N., Roudaut C., Noulet F., Garcia L., Danos O., et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther 14 (2007) 733-740
55. Martin P.T., Xu R., Rodino-Klapac L.R., Oglesbay E., Camboni M., Montgomery C.L., Shontz K., Chicoine L.G., Clark K.R., Sahenk Z., et al. Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. Am J Physiol Cell Physiol 296 (2009) C476-C488
56. Xu R., Camboni M., and Martin P.T. Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism. Neuromuscul Disord 17 (2007) 209-220
57. Xu R., Chandrasekharan K., Yoon J.H., Camboni M., and Martin P.T. Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. Am J Pathol 171 (2007) 181-199
58. Brandan E., Cabello-Verrugio C., and Vial C. Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol 27 (2008) 700-708
59. Darabi R., Santos F.N., and Perlingeiro R.C. The therapeutic potential of embryonic and adult stem cells for skeletal muscle regeneration. Stem Cell Rev 4 (2008) 217-225
60. Cerletti M., Jurga S., Witczak C.A., Hirshman M.F., Shadrach J.L., Goodyear L.J., and Wagers A.J. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell 134 (2008) 37-47
61. Sampaolesi M., Blot S., D'Antona G., Granger N., Tonlorenzi R., Innocenzi A., Mognol P., Thibaud J.L., Galvez B.G., Barthelemy I., et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444 (2006) 574-579
62. Guttinger M., Tafi E., Battaglia M., Coletta M., and Cossu G. Allogeneic mesoangioblasts give rise to alpha-sarcoglycan expressing fibers when transplanted into dystrophic mice. Exp Cell Res 312 (2006) 3872-3879
63. Cossu G., and Sampaolesi M. New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. Trends Mol Med 13 (2007) 520-526
64. Welch E.M., Barton E.R., Zhuo J., Tomizawa Y., Friesen W.J., Trifillis P., Paushkin S., Patel M., Trotta C.R., Hwang S., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007) 87-91
65. Schmitz A., and Famulok M. Chemical biology: ignore the nonsense. Nature 447 (2007) 42-43
66. Cohn R.D., van Erp C., Habashi J.P., Soleimani A.A., Klein E.C., Lisi M.T., Gamradt M., ap Rhys C.M., Holm T.M., Loeys B.L., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13 (2007) 204-210
67. Miura P., and Jasmin B.J. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?. Trends Mol Med 12 (2006) 122-129
68. Wells D.J. Treatments for muscular dystrophy: increased treatment options for Duchenne and related muscular dystropies. Gene Ther 15 (2008) 1077-1078
69. Millay D.P., Sargent M.A., Osinska H., Baines C.P., Barton E.R., Vuagniaux G., Sweeney H.L., Robbins J., and Molkentin J.D. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 14 (2008) 442-447. Inhibition of cyclophilin D significantly reduced muscle pathology in two dystrophic mouse models. Cyclophilin D plays a role in regulating mitochondrial sensitivity to calcium overload, suggesting that mitochondrial-dependent necrosis may be a prominent disease mechanism in muscular dystrophy that may be amenable to pharmacological intervention.
70. Reutenauer J., Dorchies O.M., Patthey-Vuadens O., Vuagniaux G., and Ruegg U.T. Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br J Pharmacol 155 (2008) 574-584
71. Federici T., and Boulis N.M. Gene-based treatment of motor neuron diseases. Muscle Nerve 33 (2006) 302-323
72. Hedlund E., Hefferan M.P., Marsala M., and Isacson O. Cell therapy and stem cells in animal models of motor neuron disorders. Eur J Neurosci 26 (2007) 1721-1737
73. Hollis II E.R., Kadoya K., Hirsch M., Samulski R.J., and Tuszynski M.H. Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol Ther 16 (2008) 296-301
74. Azzouz M., Le T., Ralph G.S., Walmsley L., Monani U.R., Lee D.C., Wilkes F., Mitrophanous K.A., Kingsman S.M., Burghes A.H., et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 114 (2004) 1726-1731
75. Foust K.D., Flotte T.R., Reier P.J., and Mandel R.J. Recombinant adeno-associated virus-mediated global anterograde delivery of glial cell line-derived neurotrophic factor to the spinal cord: comparison of rubrospinal and corticospinal tracts in the rat. Hum Gene Ther 19 (2008) 71-82
76. Dodge J.C., Haidet A.M., Yang W., Passini M.A., Hester M., Clarke J., Roskelley E.M., Treleaven C.M., Rizo L., Martin H., et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther 16 (2008) 1056-1064
77. Aebischer P., Schluep M., Deglon N., Joseph J.M., Hirt L., Heyd B., Goddard M., Hammang J.P., Zurn A.D., Kato A.C., et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 2 (1996) 696-699
78. Mohajeri M.H., Figlewicz D.A., and Bohn M.C. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum Gene Ther 10 (1999) 1853-1866
79. Klein S.M., Behrstock S., McHugh J., Hoffmann K., Wallace K., Suzuki M., Aebischer P., and Svendsen C.N. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther 16 (2005) 509-521
80. Meyer K., Marquis J., Trub J., Nlend Nlend R., Verp S., Ruepp M.D., Imboden H., Barde I., Trono D., and Schumperli D. Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum Mol Genet 18 (2009) 546-555